| Authors: |
Debing Y; Aligos Belgium BV, Leuven, Belgium. Electronic address: ydebing@aligos.com., Vanrusselt H; Aligos Belgium BV, Leuven, Belgium., Degrauwe L; Laboratory of Host Pathogen Interactions, Department of Biosystems, KU Leuven, Leuven, Belgium., Silva de Oliveira DA; Laboratory of Host Pathogen Interactions, Department of Biosystems, KU Leuven, Leuven, Belgium., Kariuki CK; Laboratory of Host Pathogen Interactions, Department of Biosystems, KU Leuven, Leuven, Belgium., Ebwanga EJ; Laboratory of Host Pathogen Interactions, Department of Biosystems, KU Leuven, Leuven, Belgium., Bashir S; Laboratory of Host Pathogen Interactions, Department of Biosystems, KU Leuven, Leuven, Belgium., Merckx W; TRANSfarm, Science, Engineering & Technology Group, KU Leuven, Leuven, Belgium., Thatikonda SK; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Rajwanshi V; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Gohil V; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Hong J; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Kum DB; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Acosta Sanchez A; Novalix, Braine-l'Alleud, Belgium., Chanda S; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Blatt LM; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Jekle A; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Symons JA; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Smith DB; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Raboisson P; Aligos Belgium BV, Leuven, Belgium., Lin TI; Aligos Belgium BV, Leuven, Belgium., Beigelman L; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Paeshuyse J; Laboratory of Host Pathogen Interactions, Department of Biosystems, KU Leuven, Leuven, Belgium. Electronic address: jan.paeshuyse@kuleuven.be. |
